{"name":"Torrent Pharmaceuticals","slug":"torrent-pharmaceuticals","ticker":"TORNTPHARM.NS","exchange":"NSE","domain":"torrentpharma.com","description":"Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, cosmo-dermatology, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Limited.","hq":"Ahmedabad, India","founded":0,"employees":"17059","ceo":"","sector":"Cardiovascular / GI / CNS Generics","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":4403.9,"stockChange":108.1,"stockChangePercent":2.52,"marketCap":"$15.6B","metrics":{"revenue":1330724940.4156928,"revenueGrowth":17.6,"grossMargin":75.6,"rdSpend":0,"netIncome":237303287.19342083,"cash":82921685.0764544,"dividendYield":0.81,"peRatio":65.7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"oncology","drugs":[{"name":"Daiichi Sankyo Inc's Benicar Tablets 40 mg","genericName":"Daiichi Sankyo Inc's Benicar Tablets 40 mg","slug":"daiichi-sankyo-inc-s-benicar-tablets-40-mg","indication":"Other","status":"phase_1"},{"name":"Torrent's Donepezil Hydrochloride Tablets 10mg","genericName":"Torrent's Donepezil Hydrochloride Tablets 10mg","slug":"torrent-s-donepezil-hydrochloride-tablets-10mg","indication":"Other","status":"phase_1"},{"name":"Torrent's Felodipine Extended-Release Tablets","genericName":"Torrent's Felodipine Extended-Release Tablets","slug":"torrent-s-felodipine-extended-release-tablets","indication":"Other","status":"phase_1"},{"name":"Warner Chilcott LLC Sarafem Tablets","genericName":"Warner Chilcott LLC Sarafem Tablets","slug":"warner-chilcott-llc-sarafem-tablets","indication":"Other","status":"phase_1"},{"name":"Forest Pharmaceuticals Inc's Bystolic Tablets","genericName":"Forest Pharmaceuticals Inc's Bystolic Tablets","slug":"forest-pharmaceuticals-inc-s-bystolic-tablets","indication":"Other","status":"phase_1"},{"name":"Torrent's Fluoxetine Tablets","genericName":"Torrent's Fluoxetine Tablets","slug":"torrent-s-fluoxetine-tablets","indication":"Other","status":"phase_1"},{"name":"Torrent's Nebivolol Tablets","genericName":"Torrent's Nebivolol Tablets","slug":"torrent-s-nebivolol-tablets","indication":"Other","status":"phase_1"},{"name":"Torrent's Quetiapine Fumarate Tablets","genericName":"Torrent's Quetiapine Fumarate Tablets","slug":"torrent-s-quetiapine-fumarate-tablets","indication":"Other","status":"phase_1"},{"name":"Tribenzor of Daichi Sankyo Inc. USA","genericName":"Tribenzor of Daichi Sankyo Inc. USA","slug":"tribenzor-of-daichi-sankyo-inc-usa","indication":"Other","status":"phase_1"},{"name":"Warner Chilcott LLC's Sarafem Tablet","genericName":"Warner Chilcott LLC's Sarafem Tablet","slug":"warner-chilcott-llc-s-sarafem-tablet","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TRC150094","genericName":"TRC150094","slug":"trc150094","indication":"Type 2 diabetes mellitus","status":"phase_3"}]}],"pipeline":[{"name":"Daiichi Sankyo Inc's Benicar Tablets 40 mg","genericName":"Daiichi Sankyo Inc's Benicar Tablets 40 mg","slug":"daiichi-sankyo-inc-s-benicar-tablets-40-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Torrent's Donepezil Hydrochloride Tablets 10mg","genericName":"Torrent's Donepezil Hydrochloride Tablets 10mg","slug":"torrent-s-donepezil-hydrochloride-tablets-10mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Torrent's Felodipine Extended-Release Tablets","genericName":"Torrent's Felodipine Extended-Release Tablets","slug":"torrent-s-felodipine-extended-release-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Warner Chilcott LLC Sarafem Tablets","genericName":"Warner Chilcott LLC Sarafem Tablets","slug":"warner-chilcott-llc-sarafem-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Forest Pharmaceuticals Inc's Bystolic Tablets","genericName":"Forest Pharmaceuticals Inc's Bystolic Tablets","slug":"forest-pharmaceuticals-inc-s-bystolic-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TRC150094","genericName":"TRC150094","slug":"trc150094","phase":"phase_3","mechanism":"TRC150094 is a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist that enhances insulin sensitivity and lipid metabolism.","indications":["Type 2 diabetes mellitus","Non-alcoholic fatty liver disease (NAFLD)"],"catalyst":""},{"name":"Torrent's Fluoxetine Tablets","genericName":"Torrent's Fluoxetine Tablets","slug":"torrent-s-fluoxetine-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Torrent's Nebivolol Tablets","genericName":"Torrent's Nebivolol Tablets","slug":"torrent-s-nebivolol-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Torrent's Quetiapine Fumarate Tablets","genericName":"Torrent's Quetiapine Fumarate Tablets","slug":"torrent-s-quetiapine-fumarate-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tribenzor of Daichi Sankyo Inc. USA","genericName":"Tribenzor of Daichi Sankyo Inc. USA","slug":"tribenzor-of-daichi-sankyo-inc-usa","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Warner Chilcott LLC's Sarafem Tablet","genericName":"Warner Chilcott LLC's Sarafem Tablet","slug":"warner-chilcott-llc-s-sarafem-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":11,"phaseCounts":{"phase_1":10,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":1181921247.71875,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":1181921247.71875},{"period":"2024-03-31","value":1103078805.7162502},{"period":"2023-03-31","value":988344014.03375},{"period":"2022-03-31","value":879220535.0500001}],"grossProfit":880678452.8850001,"grossProfitHistory":[{"period":"2025-03-31","value":880678452.8850001},{"period":"2024-03-31","value":811941177.7675},{"period":"2023-03-31","value":693033148.5},{"period":"2022-03-31","value":614218904.04875}],"rdSpend":3176924.1075000004,"rdSpendHistory":[{"period":"2025-03-31","value":3176924.1075000004},{"period":"2024-03-31","value":2582686.82375},{"period":"2023-03-31","value":3265694.17625},{"period":"2022-03-31","value":4036427.2437500004}],"sgaSpend":208754826.73375002,"operatingIncome":305584173.3725,"operatingIncomeHistory":[{"period":"2025-03-31","value":305584173.3725},{"period":"2024-03-31","value":268644336.88125},{"period":"2023-03-31","value":223493791.2075},{"period":"2022-03-31","value":184781686.4025}],"netIncome":199602110.46875,"netIncomeHistory":[{"period":"2025-03-31","value":199602110.46875},{"period":"2024-03-31","value":172984666.44250003},{"period":"2023-03-31","value":130046062.01125},{"period":"2022-03-31","value":81165084.7425}],"eps":56.47,"epsHistory":[{"period":"2025-03-31","value":56.47},{"period":"2024-03-31","value":48.94},{"period":"2023-03-31","value":36.79},{"period":"2022-03-31","value":22.96}],"cash":59891598.855000004,"cashHistory":[{"period":"2025-03-31","value":59891598.855000004},{"period":"2024-03-31","value":87218159.0775},{"period":"2023-03-31","value":53108521.24875},{"period":"2022-03-31","value":41607053.400000006}],"totalAssets":1565459118.0525,"totalLiabilities":772722561.3937501,"totalDebt":334435490.07000005,"equity":792736556.65875,"operatingCashflow":269976932.26625,"operatingCashflowHistory":[{"period":"2025-03-31","value":269976932.26625},{"period":"2024-03-31","value":341094289.58000004},{"period":"2023-03-31","value":247316544.59875003},{"period":"2022-03-31","value":188295936.77125}],"capex":-63900872.901250005,"capexHistory":[{"period":"2025-03-31","value":-63900872.901250005},{"period":"2024-03-31","value":-45197541.5925},{"period":"2023-03-31","value":-59939639.127500005},{"period":"2022-03-31","value":-21155473.91375}],"freeCashflow":206076059.365,"dividendsPaid":-113106644.18625,"buybacks":null,"employees":17059,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":89709987.125,"ebitda":111223674.37500001,"period":"2025-12-31","revenue":339519404.125,"epsBasic":18.77,"netIncome":66316463.12500001,"rdExpense":null,"epsDiluted":18.77,"grossProfit":256075539.50000003,"operatingIncome":92112000.75},{"sga":null,"ebit":87621279.625,"ebitda":108926096.12500001,"period":"2025-09-30","revenue":338997227.25,"epsBasic":17.45,"netIncome":61721306.62500001,"rdExpense":null,"epsDiluted":17.45,"grossProfit":255448927.25000003,"operatingIncome":91798694.625},{"sga":null,"ebit":82921687.75,"ebitda":103913198.125,"period":"2025-06-30","revenue":326673853,"epsBasic":16.19,"netIncome":57230585.50000001,"rdExpense":null,"epsDiluted":16.19,"grossProfit":245840872.75000003,"operatingIncome":86785796.625},{"sga":null,"ebit":75213312.72125001,"ebitda":96197512.62,"period":"2025-03-31","revenue":303828614.71875,"epsBasic":null,"netIncome":52034925.59375,"rdExpense":null,"epsDiluted":null,"grossProfit":216156161.76000002,"operatingIncome":79690457.2475},{"sga":null,"ebit":78117660.5,"ebitda":98900300.125,"period":"2024-12-31","revenue":288450505.75,"epsBasic":14.88,"netIncome":52530993.625,"rdExpense":null,"epsDiluted":14.88,"grossProfit":218165498.37500003,"operatingIncome":74671293.125},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":13.37,"netIncome":null,"rdExpense":null,"epsDiluted":13.37,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":4403.9,"previousClose":4295.8,"fiftyTwoWeekHigh":4555.1,"fiftyTwoWeekLow":3102,"fiftyTwoWeekRange":"3102.0 - 4555.1","fiftyDayAverage":4232.84,"twoHundredDayAverage":3899.13,"beta":0.14,"enterpriseValue":15771255931.922024,"forwardPE":68,"priceToBook":17.65,"priceToSales":11.7,"enterpriseToRevenue":11.85,"enterpriseToEbitda":36.81,"pegRatio":0,"ebitda":428469903.78368,"ebitdaMargin":32.2,"freeCashflow":0,"operatingCashflow":0,"totalDebt":294716630.9235456,"debtToEquity":33.4,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"1.7 - Buy","recommendationKey":"buy","numberOfAnalysts":27,"targetMeanPrice":4564.93,"targetHighPrice":5100,"targetLowPrice":3970,"dividendRate":35,"payoutRatio":0.48,"fiveYearAvgDividendYield":1.04,"exDividendDate":1771372800,"insiderHeldPercent":71.1,"institutionHeldPercent":15.1,"sharesOutstanding":338445440,"floatShares":103941076,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":67.01,"epsForward":64.76,"revenuePerShare":376.39,"bookValue":249.47,"officers":[{"age":null,"name":"Mr. Aman  Mehta","title":"MD & Whole-Time Director"},{"age":53,"name":"Mr. Sudhir  Menon CA, CWA","title":"Executive Director of Finance & CFO"},{"age":57,"name":"Mr. Ashish  Hajarnish M.Pharm","title":"Executive Director of Operations"},{"age":null,"name":"Ms. Geena V. Malhotra","title":"Chief Technology Officer"},{"age":null,"name":"Mr. Chintan M. Trivedi","title":"Company Secretary & Compliance Officer"},{"age":72,"name":"Mr. Jaydip  Bhatt","title":"Vice President of Human Resource"},{"age":null,"name":"Mr. Abdullah Salam Said Al Abri","title":"Chief Customer Service Officer"},{"age":null,"name":"Mr. Sanjay  Gupta","title":"President and CEO of Torrent Pharma USA"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.torrentpharma.com","phone":"91 79 2659 9000"}}